CN102680707B - 蛋白质cops2在制备诊断胃癌的试剂中的应用及诊断试剂盒 - Google Patents
蛋白质cops2在制备诊断胃癌的试剂中的应用及诊断试剂盒 Download PDFInfo
- Publication number
- CN102680707B CN102680707B CN201210149141.0A CN201210149141A CN102680707B CN 102680707 B CN102680707 B CN 102680707B CN 201210149141 A CN201210149141 A CN 201210149141A CN 102680707 B CN102680707 B CN 102680707B
- Authority
- CN
- China
- Prior art keywords
- cops2
- solution
- protein
- diagnosis
- gastric cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000005718 Stomach Neoplasms Diseases 0.000 title claims abstract description 55
- 238000009007 Diagnostic Kit Methods 0.000 title claims abstract description 16
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 14
- 102000004169 proteins and genes Human genes 0.000 title abstract description 8
- 108090000623 proteins and genes Proteins 0.000 title abstract description 8
- 238000002360 preparation method Methods 0.000 title abstract description 4
- 210000002966 serum Anatomy 0.000 claims abstract description 37
- 102000004190 Enzymes Human genes 0.000 claims abstract description 14
- 108090000790 Enzymes Proteins 0.000 claims abstract description 14
- 239000000427 antigen Substances 0.000 claims abstract description 14
- 108091007433 antigens Proteins 0.000 claims abstract description 14
- 102000036639 antigens Human genes 0.000 claims abstract description 14
- 239000000758 substrate Substances 0.000 claims abstract description 13
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims abstract description 12
- 238000002965 ELISA Methods 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 9
- 230000000694 effects Effects 0.000 claims abstract description 8
- 238000005406 washing Methods 0.000 claims abstract description 4
- 239000002253 acid Substances 0.000 claims abstract description 3
- 238000006555 catalytic reaction Methods 0.000 claims abstract description 3
- 239000007790 solid phase Substances 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 44
- 206010017758 gastric cancer Diseases 0.000 claims description 28
- 201000011549 stomach cancer Diseases 0.000 claims description 27
- 101000726004 Homo sapiens COP9 signalosome complex subunit 2 Proteins 0.000 claims description 24
- 238000003745 diagnosis Methods 0.000 claims description 21
- 102100027652 COP9 signalosome complex subunit 2 Human genes 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 229940088598 enzyme Drugs 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 238000013016 damping Methods 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 7
- 238000007865 diluting Methods 0.000 claims description 7
- 101800004937 Protein C Proteins 0.000 claims description 6
- 102000017975 Protein C Human genes 0.000 claims description 6
- 101800001700 Saposin-D Proteins 0.000 claims description 6
- 229960000856 protein c Drugs 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- VOZKAJLKRJDJLL-UHFFFAOYSA-N 2,4-diaminotoluene Chemical compound CC1=CC=C(N)C=C1N VOZKAJLKRJDJLL-UHFFFAOYSA-N 0.000 claims description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 230000002018 overexpression Effects 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
- 238000001261 affinity purification Methods 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims description 2
- 229940098773 bovine serum albumin Drugs 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 239000001632 sodium acetate Substances 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- 238000013399 early diagnosis Methods 0.000 abstract description 9
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 108090000144 Human Proteins Proteins 0.000 abstract description 2
- 102000003839 Human Proteins Human genes 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 239000011148 porous material Substances 0.000 abstract 1
- 201000000498 stomach carcinoma Diseases 0.000 description 27
- 239000000523 sample Substances 0.000 description 20
- 206010028980 Neoplasm Diseases 0.000 description 12
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 102100028879 COP9 signalosome complex subunit 8 Human genes 0.000 description 5
- 101000916502 Homo sapiens COP9 signalosome complex subunit 8 Proteins 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 108010070033 COP9 Signalosome Complex Proteins 0.000 description 4
- 208000010749 gastric carcinoma Diseases 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000011902 gastrointestinal surgery Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 101150024074 rub1 gene Proteins 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 102000053987 NEDD8 Human genes 0.000 description 1
- 108700004934 NEDD8 Proteins 0.000 description 1
- 101150107958 NEDD8 gene Proteins 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101100532088 Oryza sativa subsp. japonica RUB2 gene Proteins 0.000 description 1
- 101100532090 Oryza sativa subsp. japonica RUB3 gene Proteins 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 102000036366 SCF complex Human genes 0.000 description 1
- 108091007047 SCF complex Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000001002 morphogenetic effect Effects 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000027874 photomorphogenesis Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210149141.0A CN102680707B (zh) | 2012-05-14 | 2012-05-14 | 蛋白质cops2在制备诊断胃癌的试剂中的应用及诊断试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210149141.0A CN102680707B (zh) | 2012-05-14 | 2012-05-14 | 蛋白质cops2在制备诊断胃癌的试剂中的应用及诊断试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102680707A CN102680707A (zh) | 2012-09-19 |
CN102680707B true CN102680707B (zh) | 2014-04-30 |
Family
ID=46812950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210149141.0A Active CN102680707B (zh) | 2012-05-14 | 2012-05-14 | 蛋白质cops2在制备诊断胃癌的试剂中的应用及诊断试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102680707B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5831059A (en) * | 1997-03-27 | 1998-11-03 | Incyte Pharmaceuticals, Inc. | Human COP9 developmental protein |
CN1302815A (zh) * | 1999-10-28 | 2001-07-11 | 上海博容基因开发有限公司 | 一种新的多肽-人cop9复合物亚单位30和编码这种多肽的多核苷酸 |
KR20090056732A (ko) * | 2007-11-30 | 2009-06-03 | (주)지노믹트리 | 건선 진단용 키트 및 칩 |
-
2012
- 2012-05-14 CN CN201210149141.0A patent/CN102680707B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5831059A (en) * | 1997-03-27 | 1998-11-03 | Incyte Pharmaceuticals, Inc. | Human COP9 developmental protein |
CN1302815A (zh) * | 1999-10-28 | 2001-07-11 | 上海博容基因开发有限公司 | 一种新的多肽-人cop9复合物亚单位30和编码这种多肽的多核苷酸 |
KR20090056732A (ko) * | 2007-11-30 | 2009-06-03 | (주)지노믹트리 | 건선 진단용 키트 및 칩 |
Non-Patent Citations (6)
Title |
---|
Oleg Tchernitsa,et al.Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression.《The Journal of Pathology》.2010,第222卷(第3期), |
Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression;Oleg Tchernitsa,et al;《The Journal of Pathology》;20101130;第222卷(第3期);310–319 * |
The COP9 Signalosome Inhibits p27kip1 Degradation and Impedes G1-S Phase Progression via Deneddylation of SCF Cul1;Xiaoming Yang,et al;《Current Biology》;20020416;第12卷(第8期);667–672 * |
Xiaoming Yang,et al.The COP9 Signalosome Inhibits p27kip1 Degradation and Impedes G1-S Phase Progression via Deneddylation of SCF Cul1.《Current Biology》.2002,第12卷(第8期), |
卵巢癌细胞卡铂耐药相关肿瘤抑制基因的表达变化及其启动子区甲基化观察;唐兆前等;《山东医药》;20101231;第50卷(第18期);22-24 * |
唐兆前等.卵巢癌细胞卡铂耐药相关肿瘤抑制基因的表达变化及其启动子区甲基化观察.《山东医药》.2010,第50卷(第18期),22-24. |
Also Published As
Publication number | Publication date |
---|---|
CN102680707A (zh) | 2012-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1727896B (zh) | 磷酸化及对应非磷酸化蛋白质多克隆抗体在制备疾病诊断试剂中的应用及其制备方法 | |
CN102680709B (zh) | 诊断试剂盒及ccdc49在制备胃癌早期诊断试剂中的应用 | |
CN106053812B (zh) | 一种用于肝癌早期筛查和诊断的多种自身抗体联合检测elisa试剂盒 | |
CN102680706B (zh) | 蛋白质ctsf在制备诊断胃癌的试剂中的应用及诊断试剂盒 | |
Chen et al. | Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting | |
CN106706912A (zh) | 诊断炎症相关肝癌的标志物及其应用 | |
CN110187109A (zh) | 一种用于贲门腺癌早期筛查的自身抗体联合检测elisa试剂盒 | |
RU2670052C1 (ru) | Антигенный полипептид для выявления в плазме крови иммунного маркера - аутоантитела к vegfr1 и его применение | |
CN107462725B (zh) | 抗FNDC4的IgG抗体作为胃癌血清标志物的应用及其试剂盒 | |
CN101344525A (zh) | 一种amacr自身抗体的检测方法及在前列腺癌诊断中的应用 | |
CN110187111A (zh) | 一种用于早期贲门癌筛查elisa试剂盒 | |
CN102680708B (zh) | 诊断试剂盒及rnf19在制备胃癌早期诊断试剂中的应用 | |
CN102680707B (zh) | 蛋白质cops2在制备诊断胃癌的试剂中的应用及诊断试剂盒 | |
CN102680687B (zh) | 蛋白质terf1在制备诊断胃癌的试剂中的应用及诊断试剂盒 | |
CN102798722B (zh) | 蛋白质nt5e在制备诊断胃癌的试剂中的应用及诊断试剂盒 | |
CN107144688B (zh) | Cd19阳性外泌体作为分子标记在制备肿瘤诊断试剂盒中的应用及试剂盒 | |
CN107449903B (zh) | 抗XRCC3的IgG抗体作为胃癌血清标志物的应用及其试剂盒 | |
CN109725154A (zh) | 一种IgG4荧光免疫层析测定试剂盒及测定方法 | |
CN102680688B (zh) | 诊断试剂盒及bfar在制备胃癌早期诊断试剂中的应用 | |
CN109085359A (zh) | 血清蛋白标志物组合在结直肠癌筛查和诊治中的应用 | |
CN114994306A (zh) | 一种蛋白质pknox1在制备诊断酒精性心肌病的试剂中的应用及诊断试剂盒 | |
CN110261618B (zh) | Sprr4蛋白作为胃癌血清生物标志物的应用及其试剂盒 | |
CN108362884B (zh) | 一种肿瘤危险度和治疗效果评估的血清及组织分子指标 | |
CN110261611A (zh) | Znf709蛋白作为胃癌血清生物标志物的应用及其试剂盒 | |
CN110687285A (zh) | 诊断试剂盒及mak16在制备系统性红斑狼疮早期诊断试剂中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20120919 Assignee: CHENGDU CAPITALBIO NEW VIEW DIAGNOSTIC TECHNOLOGY Co.,Ltd. Assignor: Shanghai Jiao Tong University Contract record no.: 2016990000394 Denomination of invention: Application of protein COPS2 (constitutive photomorphogenic homolog subunit 2) to preparation of reagent for diagnosing gastric cancers and diagnostic kit Granted publication date: 20140430 License type: Exclusive License Record date: 20160913 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: CHENGDU CAPITALBIO NEW VIEW DIAGNOSTIC TECHNOLOGY Co.,Ltd. Assignor: SHANGHAI JIAO TONG University Contract record no.: 2016990000394 Date of cancellation: 20231229 |